Table 1. Characteristics of the African American prostate cancer patient population with tumor DNA methylation data.
| FHCRC patients (n=44) | EVMS patients (n=32) | Combined study population (n=76) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| No. | % | Mean (SD) | No. | % | Mean (SD) | Pa | No. | % | Mean (SD) | |
| Age at diagnosis (yr) | 58.1 (6.0) | 59.3 (6.1) | 0.21 | 58.6 (6.0) | ||||||
| Gleason score | <0.01 | |||||||||
| 5-6 | 14 | 31.8 | 6 | 18.8 | 20 | 26.3 | ||||
| 7(3+4) | 20 | 45.5 | 17 | 53.1 | 37 | 48.7 | ||||
| 7(4+3) | 6 | 13.6 | 5 | 15.6 | 11 | 14.5 | ||||
| 8-10 | 4 | 9.1 | 4 | 12.5 | 8 | 10.5 | ||||
| Pathological stage | <0.01 | |||||||||
| Local (pT1/T2) | 25 | 56.8 | 14 | 43.8 | 39 | 51.3 | ||||
| Regional (pT3) | 19 | 43.2 | 18 | 56.2 | 37 | 48.7 | ||||
| Recurrence status | <0.01 | |||||||||
| No recurrence | 20 | 45.4 | 18 | 56.3 | 38 | 50.0 | ||||
| Recurrence | 5 | 11.4 | 14 | 43.5 | 19 | 25.0 | ||||
| Mets/PCa Death | 0 | 0.0 | 12 | 37.5 | 12 | 15.8 | ||||
| Unknown | 19 | 43.2 | 0 | 0.0 | 19 | 25.0 | ||||
| Tumor aggressivenessb | <0.01 | |||||||||
| Low | 19 | 43.2 | 10 | 31.3 | 29 | 38.2 | ||||
| High | 25 | 56.8 | 22 | 68.7 | 47 | 61.8 | ||||
Abbreviations: PCa, prostate cancer; SD, standard deviation
a
P value calculated using a t-test (age) or chi-square test (categorical variables)
b
Composite variable of tumor aggressiveness (High = one or more of the following: PCa recurrence or death; Gleason sum (7=4+3 or 8-10); and/or regional stage)